Takeda Pharmaceutical are launching an open innovation initiative inviting researchers to submit their proposals addressing novel technologies and approaches related to immuno‑oncology of tumours. One‑year projects will be funded up to JPY 10,000,000 or equivalent amount, including indirect costs.
Projects should address one of two areas:
REF#3 Induction of anti‑tumour effects in ‘cold’ tumours insensitive to immune checkpoint inhibitors.
- Clinically relevant models that faithfully recapitulate the microenvironment of ‘cold’ tumours
- Proposals addressing ...